NOLA.com4h
New prostate cancer drug can extend life expectancy by 8 months, Baton Rouge doctor says
"It’s crucial that patients and their families know about this new option," said Dr. William Russell, an oncology radiologist ...
CURE22h
Dive Into March 2025 FDA Approvals Across Cancer Subtypes
Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...
Florida Cancer Specialists & Research Institute Expands Availability Of Advanced Radiopharmaceutical Therapies
Florida Cancer Specialists & Research Institute, LLC (FCS) continues to expand the availability of life-changing and ...
MPR1d
FDA Expands Approval of Pluvicto in PSMA-Positive Metastatic CRPC
The Food and Drug Administration (FDA) has expanded the approval of Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) to include patients with ...
The Pharma Letter1d
Celine Wilke leaves Novartis to become ITM CMO
Privately-held German radiopharmaceutical company Isotope Technologies Munich (ITM) has announced the appointment of Celine ...
ASP Isotopes Inc. Completes Commissioning of First Quantum Enrichment Laser System and Starts Production of Commercial Samples of Ytterbium-176
Ytterbium-176 is a critical material used in the production of radioisotopes for oncology treatments, including Novartis’ Pluvicto. - The ...
The Bakersfield Californian2d
ASP Isotopes Inc. Completes Commissioning of First Quantum Enrichment Laser System and Starts ...
Ytterbium-176 is a critical material used in the production of radioisotopes for oncology treatments, including Novartis’ Pluvicto.
PMLive2d
Novartis’ Pluvicto granted FDA approval for expanded prostate cancer use
Novartis’ radioligand therapy Pluvicto (lutetium Lu 177 vipivotide tetraxetan) has been approved by the US Food and Drug ...
STAT3d
Emotional whiplash for PTC Therapeutics
Pluvicto, Novartis’ blockbuster radiopharmaceutical for prostate cancer, has been greenlighted by the FDA for use earlier in ...
The Pharma Letter3d
Novartis’ Pluvicto gets FDA green light for mCRPC
Novartis (NOVN: VX) announced late Friday that the US Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 ...
Medscape3d
FDA Approves Pluvicto for Earlier Use in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor ...
Pharmabiz3d
Novartis radioligand therapy, Pluvicto gets US FDA approval for earlier use before chemotherapy in PSMA-positive mCRPC
Novartis radioligand therapy, Pluvicto gets US FDA approval for earlier use before chemotherapy in PSMA-positive mCRPC: Basel Monday, March 31, 2025, 13:00 Hrs [IST] Novartis anno ...